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Abstract
BACKGROUND
Posterior ischemic optic neuropathy (PION) is a vascular disorder that oc-
curs in the posterior part of the optic nerve and therefore usually does not 
present with optic disc edema. 
CASE REPORT
We report here a case of PION with an uncharacteristic presentation. It 
highlights the importance of understanding the different pathophysiolo-
gies of PION and anterior ischemic optic neuropathy (AION) to help differ-
entiate between the two clinically, and includes a literature review of PION.
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INTRODUCTION
Ischemic optic neuropathies are often differentiated based on the lo-
cation of the ischemia and the etiology. Anterior ischemic optic neu-
ropathy (AION) involves the anterior 1mm of the optic nerve head and 
often presents with edema at the optic disc, resulting in visible optic 
nerve swelling. AION can be further classified based on its etiology; 
non-arteritic (NA-AION) or arteritic (A-AION), which is almost always 
associated with giant cell arteritis. Posterior ischemic optic neuropathy 
(PION) is an ischemia that presents at any location behind the optic disc 
and, by definition, does not cause optic nerve swelling.1,2 PION is a di-
agnosis of exclusion and is more rare than AION. There are overlapping 
characteristics between AION and PION, including systemic risk factors 
and sudden painless vision loss. We can differentiate between AION and 
PION clinically if we thoroughly understand the pathophysiologies of 
the diseases. Currently, different treatment options are being investi-
gated and systemic corticosteroids seem to show promising results for 
both conditions.3,4 
We present here a case that highlights the importance of understanding 
the pathogenesis and clinical presentation of PION to help differentiate 
PION from AION. Understanding the different types of ischemic optic 
neuropathies is important for the primary eye care provider to provide 
prompt and appropriate treatment for patients.
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CASE REPORT
A 60-year-old South Asian woman presented for an ocular emergency exam. The patient’s chief complaint 
was neck pain that preceded sudden vision loss OS. The patient reported that diffuse neck pain on the left side 
started approximately one week previously and vision loss began 3 days previously. At the exam, she reported 
worsening vision, mild pain in the eye (3 out of 10), frontal headache and photophobia. The patient denied 
any redness, discharge, jaw claudication, scalp tenderness, fever, malaise or history of recent ocular trauma or 
surgery. She denied flashes or floaters in her vision. Her medical history was positive for hypothyroidism and 
medication included Synthroid.
Presenting aided visual acuity was 6/6+2 OD and 6/21-2 OS at distance. Pinhole acuity at distance was 6/18 OS. 
Broad H testing showed no restrictions, no pain on eye movement, and no diplopia in any gaze. Amsler grid 
testing was normal OD; OS showed a scotoma in the inferior nasal quadrant. Red cap testing showed 75% 
saturation OS compared to 100% saturation OD. Ishihara color testing was normal OD, but only the first plate 
was seen with OS. Pupils were equally round and reactive to light, with grade 1 RAPD in OS. Anterior segment 
evaluation by slit lamp was unremarkable. Angles by Van Herick measured 1:0.25. Intraocular pressures were 
12mmHg OU with Goldmann Applanation Tonometry. Four-mirror gonioscopy was open to ciliary body in 
the inferior quadrant and scleral spur in the other quadrants OU. Dilated fundus examination showed grade 1 
cortical cataract OU with trace posterior subcapsular cataract OS. Fundus examination (Figs. 1,2) using fundus 
biomicroscopy and binocular indirect ophthalmoscopy revealed clear vitreous and pink and distinct nerve 
with a cup to disc ratio of 0.65 OU. The nerves were large and the rim tissue was intact in both eyes. The optic 
nerve was negative for disc edema and pallor, and no signs of RNFL defects were observed OU. The optic nerve 
findings were consistent with what was measured on the SD-OCT (Fig. 3). The macula was flat and had even 
macular pigment; the vasculature showed a 2 to 3 ratio with normal course and caliber OU. The peripheral 
retina was negative for holes, tears, retinal detachment, or any pathology OU. The ganglion cell analysis (Fig. 
4) and HD raster macula scans (Figs. 5,6) showed no loss of ganglion cells and no abnormalities of the macula 
OU. Humphrey Visual Field 30-2 (Figs. 7,8) was performed before dilation. The right eye was unremarkable 
with non-specific superior defects throughout the field. The left eye revealed a deep inferior altitudinal visual 
field defect and superior arcuate defect. The inferior defect was deeper than the superior defect. The visual 
field defect in the left eye did not match the clinical findings in the optic nerve, retina or OCT, suggesting a 
pathology posterior to the lamina.
An urgent referral for bloodwork including Erythrocyte Sedimentation Rate (ESR) and C-reactive Protein (CRP) 
was made to the family physician and a consult request was made to the on-call ophthalmologist to rule out a pos-
terior ischemic optic neuropathy secondary to giant cell arteritis. MRI of the orbit and chiasm along with MRI of 
the neck was ordered to rule out any lesions more posterior or the possibility of carotid dissection. The minimal 
eye pain was to be re-evaluated once the cause of the vision loss was diagnosed.
Bloodwork revealed normal ESR, CRP and platelets. The on-call ophthalmologist saw the patient the next day. 
The exam findings were similar to those measured the day before, except that the patient’s visual acuity in OS 
had further deteriorated to 20/100. Despite the lack of classic signs and symptoms, the patient was initially 
diagnosed with NA-AION by the ophthalmologist. No treatment was initiated at the time of investigation and 
vision slowly improved over the next 12 months. No optic nerve pallor or RNFL loss was noted at a one-year 
follow-up. The visual field defect was still present, but had improved. Further reflection on the case pointed to 
a diagnosis of PION, given the lack of clinical signs. The MRI results were unremarkable. 
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Figure 1: Retinal photograph OD at the time of the initial examination shows no disc edema, hemorrhage or pallor of the 
optic nerve, even pigment of the macula, and healthy vasculature.
Figure 2: Retinal photograph OS at the time of the initial examination shows no disc edema, hemorrhage or pallor of the optic 
nerve, even pigment of the macula, and healthy vasculature.
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Figure 3: Zeiss Cirrus OCT Optic Nerve Head and RNFL OU at the initial examination shows healthy RNFL with no signs  
of optic nerve head edema OU.
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Figure 4: Zeiss Cirrus OCT Macula Cube (Ganglion Cell Layer Analysis) OU at the initial examination shows healthy GCC 
layer in both eyes. There is no hemispheric deterioration that may correlate to the visual field defect in the right eye.
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Figure 5: Zeiss Cirrus OCT HD raster (macula) OD at the initial examination shows healthy macula and no pathology that 
may be responsible for the deterioration of vision.
C A NA D I A N  JO U R NA L  o f  O P T O M E T RY    |    R EV U E  C A NA D I E N N E  D ’O P T O M É T R I E     VO L .  8 2   NO.  216
CASE REPORT
Figure 6: Zeiss Cirrus OCT HD raster (macula) OS at the initial examination shows healthy macula.
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Figure 7: Humphrey Visual Field 30-2 SITA Standard OD at the follow-up shows mild scattered superior defects.
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Figure 8: Humphrey Visual Field 30-2 SITA Standard OS at the follow-up shows deep inferior altitudinal defect and superior 
arcuate defect.
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DISCUSSION
Ischemic optic neuropathies can be differentiated based on the location of the ischemia. More commonly, the isch-
emia is in the anterior lamina and causes classical clinical signs in the optic nerve and vision. When the ischemia 
is behind the lamina, visual disruption occurs, but the optic nerve is left unaffected. AION and PION are similar in 
that they can be further classified into arteritic and non-arteritic etiologies.
To further understand PION, it is helpful to review the pathology of AION. AION is typically classified as arteritic (A-
AION) or non-arteritic (NA-AION). The difference between A-AION and NA-AION depends on whether the patho-
genesis is secondary to vasculitis or other entities.5 A-AION is most commonly caused by giant cell arteritis (GCA), 
a specific type of vasculitis. Bloodwork including ESR and CRP, along with a thorough case history, is necessary to 
investigate the presence of inflammation if there is any suspicion of A-AION. Symptoms, including the presence of 
headache, scalp tenderness, as well as tenderness over the affected artery and jaw claudication, are often present in 
patients with GCA. In addition, myalgia, fatigue, weight loss, and decreased appetite are frequently seen. If GCA is 
suspected, immediate treatment is required.1,6 GCA is a true ocular emergency and permanent vision loss will ensue if 
it is not managed as soon as possible.
The pathogenesis of NA-AION remains unclear, but seems to encompass common sources of ischemic injury 
including, but not limited to, thromboembolism, systemic hypotension, and atherosclerotic occlusion.5 On the 
other hand, NA-AION is not due to inflammation, indicating that inflammatory markers would not be elevated 
in a lab test. In the case described here, ESR, CRP and platelets were normal, which ruled out A-AION. In ad-
dition, the visual field presentation was more consistent with NA-AION than with A-AION. The patient pre-
sented with unilateral inferior altitudinal visual field defect, which is a common presentation for NA-AION.7 
Studies show that there is value in using OCT for the diagnosis of NA-AION.8 After acute axonal swelling and 
then thinning, both GCC and RNFL would show thickening and then thinning of the layers.8 Furthermore, the 
location and severity of the visual field defect significantly correlates with RNFL thinning.8 Therefore, both A-
AION and NA-AION should present with optic disc edema and either thickening (acute stage) or thinning (af-
ter resolution of the edema) of RNFL and GCC on OCT, which were absent in this case.8,9 Similarly, a retinal or 
other optic nerve pathology can also be ruled out as a cause of the visual field defect due to the normal macula 
and optic nerve OCT.10,11 The nerve fiber layer showed a 31-micron difference in the superior nasal, suggesting 
a mild amount of asymmetry between the right eye and left eye. The asymmetry in RNFL in the superior nasal 
clock and the lack of hemispheric thinning seen in ganglion cell analysis in the left eye does not explain the 
diffuse and deep scotoma in the visual field OS.8,12 Based on the patient’s age, symptoms, clinical findings, and 
lab results, it may still be safe to assume that this was a non-arteritic ischemic event, however the location of 
the ischemia was likely posterior, suggesting a diagnosis of PION. 
PION can be divided into three different types; arteritic, non-arteritic, and peri-operative.13 The exact epide-
miology or prevalence of PION is unknown, but in a study by Hayreh, the median age of non-arteritic PION 
was 61.5 years and that of arteritic PION was 73.5 years.13 There is considerable overlap with AION in terms 
of symptoms, systemic association, diagnostic testing, and treatment protocol. As with AION, some of the risk 
factors include anemia, intraoperative hypotension, diabetes, obesity, and intraoperative blood loss, which can 
decrease the ocular perfusion pressure.14-16 
To further understand why PION is a diagnosis by exclusion, it is helpful to review the vascular system of the 
optic nerve. The optic nerve head is supplied by the central retinal artery (CRA) and short posterior ciliary 
arteries (SPCA).17 The posterior part of the nerve is supplied by the CRA in the centre and pial vascular plexus, 
which is responsible for the peripheral vascular system.13 In AION, the ischemia occurs due to the SPCA.3 The 
SPCA is the end-point of the arterial system without any anastomoses to other arterial branches.13 No other 
blood vessels can compensate for the SPCA if they become ischemic.13 In the posterior part of the optic nerve, 
the pial vascular plexus originates from the peripapillary choroid, circle of Zinn and Haller, central retinal 
artery, and ophthalmic artery.13 The pial vascular plexus is not the end-point of the arterial system, so blood is 
able to freely relocate within the collateral plexus. This serves as a protective factor for the posterior part of 
the nerve if a region of a collateral system becomes ischemic.13 Therefore, there is less chance for ischemia to 
occur in the posterior part of the optic nerve. 
Among NA-PION cases described by Hayreh, 24 of 35 eyes presented with a visual acuity of 20/100 or worse.13 At the 
initial examination, our patient presented with a visual acuity of 20/70. However, the next-day assessment by an oph-
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thalmologist showed further deterioration of visual acuity to 20/100.13 In the study by Hayreh, all of the patients under-
went an extensive ocular examination along with fluorescein angiography, magnetic resonance imaging, and neurological 
evaluation to exclude any other ocular, optic nerve, or neurological disorder.13 In this case, with mild ocular pain (3/10) 
and lack of optic disc edema, MRI was beneficial for ruling out retrobulbar optic neuritis secondary to multiple sclerosis. 
Further, demyelinating optic neuritis most commonly occurs in young women 20 to 45 years of age.18,19 
Visual field defects in ischemic optic neuropathies can vary depending on which part of the RNFL is damaged. 
For PION, studies show that a central defect is the most common visual field defect, but other defects might be 
observed.1,13 The type of visual field defect is determined by which vascular system is affected.20 In the retina, the 
papillomacular bundle of RNFL exits from the temporal aspect and makes up the central core of the optic nerve.1 
The posterior part of the optic nerve is not supplied by the CRA, only by the terminal capillary ends from the pial 
vascular plexus.12 This terminal plexus is called the watershed zone.1 The watershed zone has been shown to be 
the most vulnerable region for ischemia.1,21 In instances of decreased perfusion, the watershed zone will be the first 
region to become ischemic because there is a lack of blood supply to the central core of the optic nerve.1 This results 
in the central visual field defect that is most commonly present in patients with PION.1 Since the pial vascular plexus 
supplies different parts of the posterior optic nerve, localized ischemia can show different types of visual field de-
fect, depending on which area of the plexus is affected and where the affected optic nerve fibres originate in the 
retina.13 In fact, Hayreh reported that only 9 of 32 eyes in his study showed central defects and the rest manifested 
a variety of visual field defects.13 In our case, the patient did not have a central defect, but rather presented with an 
inferior altitudinal defect with some nasal scotoma. Based on the pathophysiology of PION, the inferior altitudinal 
defect seen in this patient is not impossible, but may be a rare form of a visual field defect.
The treatment for NA-PION is similar to that for NA-AION. According to Hayreh, systemic corticosteroid treatment 
usually results in significant improvements in visual acuity and visual field.22-24 In one study by Hayreh, a cohort of 
696 consecutive eyes with NA-AION, seen within 2 weeks of onset, and initial visual acuity of 20/70 or worse was 
assigned to systemic corticosteroid treatment or non-treatment.22 Six months after the initial visit, 69.8% of patients 
in the corticosteroid treatment group showed an improvement in visual acuity, compared to only 37.1% in the non-
treated group.22 A similar comparison was done on improvements in visual field defects; after 6 months, 40.1% of the 
systemic corticosteroid-treated group showed improvement compared to only 24.5% of those who did not receive 
corticosteroid therapy.22 In these studies, corticosteroid treatment was continued until there was complete resolu-
tion of the optic disc edema. However, because PION does not present with optic disc edema, the benefits and dura-
tion of treatment with corticosteroids are still being investigated.
There is no definite follow-up protocol for PION. In one study, Hayreh initiated steroid treatment for 2 days, fol-
lowed by rapid tapering and follow-up assessment in less than 2 weeks for both NA-PION and perioperative PION.13 
However, long-term follow-up after initial onset varied from 1.3 to 214 months for NA-PION, 1.3 to 55.6 months 
for A-PION and 4.6 to 56.6 months for perioperative PION. Hayreh explained that the prognosis regarding visual 
recovery can also vary depending on the type of PION. In NA-PION, vision can be improved with high-dose cortico-
steroid therapy, whereas treatment of A-PION only prevents further vision loss. In NA-PION, spontaneous resolu-
tion of visual acuity and field may still occur without any treatment. In fact, only 5 of 16 treated eyes remained with 
stable vision, whereas 9 of 16 untreated eyes remained stable.13
CONCLUSION
Posterior ischemic optic neuropathy (PION)is a diagnosis of exclusion that can be made after a thorough patient 
history, presentation and appropriate diagnostic testing. This case shows the importance of co-management with 
ophthalmologists and family physicians in any case of suspected ischemic optic neuropathy, including suspected 
PION. As the primary eye care providers, optometrists need to be familiar with the differences between optic neu-
ropathies, and how to find appropriate and prompt management for their patients. l 
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